The Russian military reconnaissance ship Yantar made a three-month voyage along the coast of Europe in search of critical energy and internet cables. The vessel is equipped with advanced surveillance ...

Vor Biopharma (NASDAQ:VOR) trading was halted on September 18, 2025, pending any announcements from the company. The stock fell over 16% this week. Separately, 10% owner Reprogrammed Interchange and ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

) has been revised to $36.46 / share. This is an increase of 2,942.55% from the prior estimate of $1.20 dated September 10, 2025. The price target is an average of many targets provided by analysts.